CompletedPhase 3

Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis

Romania19 participantsStarted 2024-08-05

Plain-language summary

The study aims to investigate the beneficial effects of fecal transplantation in patients diagnosed with liver cirrhosis (regardless of etiology).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of liver cirrhosis according to current protocols. * Conscious and cooperative adult patients. Exclusion Criteria: * Patients with hemodynamic and/or respiratory instability. * Patients with contraindications for colonoscopy or fecal transplantation. * Patients with acute or chronic infections with HIV, Tuberculosis, MDR Enterobacteria, CMV, parasites, fungi. * Associated oncological pathology. * Patients with other causes of severe immunodeficiencies. * Lack of compliance with the conditions imposed by the research project. * Patients who do not sign the informed consent.

What they're measuring

Liver Stiffness by Transient Elastography (FibroScan)

Timeframe: At one month post-FMT.

Implications of Fecal Microbiota Transplantation in Modulating Hepatic Encephalopathy

Timeframe: At one month post-FMT.

Trial details

NCT IDNCT06478602

SponsorCristian Ichim

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-30

Results submitted2025-12-02

View on ClinicalTrials.gov More Liver Cirrhosis trials